Futility Interim Analysis Based on Probability of Success Using a Surrogate Endpoint
Pharmaceutical Statistics · 2024
DOI: 10.1002/pst.2410 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceutical Statistics, 2024. Verfasst von Ronan Fougeray und 5 weiteren Autor:innen. Beteiligte Einrichtung: Institut de Recherches Internationales Servier (IRIS), Gif-sur-Yvette, France. Hauptthemen laut MEDLINE: Bayes Theorem, Endpoint Determination, Biomarkers, Probability. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Institut de Recherches Internationales Servier (IRIS), Incorporated Research Institutions for Seismology.
Abstract (Originalsprache)
In clinical trials with time‐to‐event data, the evaluation of treatment efficacy can be a long and complex process, especially when considering long‐term primary endpoints. Using surrogate endpoints to correlate the primary endpoint has become a common practice to accelerate decision‐making. Moreover, the ethical need to minimize sample size and the practical need to optimize available resources have encouraged the scientific community to develop methodologies that leverage historical data. Relying on the general theory of group sequential design and using a Bayesian framework, the methodology described in this paper exploits a documented historical relationship between a clinical “final” endpoint and a surrogate endpoint to build an informative prior for the primary endpoint, using surrogate data from an early interim analysis of the clinical trial. The predictive probability of success of the trial is then used to define a futility‐stopping rule. The methodology demonstrates substantial enhancements in trial operating characteristics when there is a good agreement between current and historical data. Furthermore, incorporating a robust approach that combines the surrogate prior with a vague component mitigates the impact of the minor prior‐data conflicts while maintaining acceptable performance even in the presence of significant prior‐data conflicts. The proposed methodology was applied to design a Phase III clinical trial in metastatic colorectal cancer, with overall survival as the primary endpoint and progression‐free survival as the surrogate endpoint.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institut de Recherches Internationales Servier (IRIS), Gif-sur-Yvette, France.
- Politecnico di Torino, Torino, Italy.
- Servier, Boston, USA.
- Saryga, Tournus, France.
ORCID-Profile: Marco Ratta, Gaëlle Saint-Hilary
Förderung
- Institut de Recherches Internationales Servier (IRIS)
- Incorporated Research Institutions for Seismology
Zitieren
APA
Fougeray, R., Vidot, L., Ratta, M., Teng, Z., Skanji, D., & Saint-Hilary, G. (2024). Futility Interim Analysis Based on Probability of Success Using a Surrogate Endpoint. Pharmaceutical Statistics. https://doi.org/10.1002/pst.2410
Vancouver
Fougeray R, Vidot L, Ratta M, Teng Z, Skanji D, Saint-Hilary G. Futility Interim Analysis Based on Probability of Success Using a Surrogate Endpoint. Pharmaceutical Statistics. 2024. doi:10.1002/pst.2410
BibTeX
@article{Fougeray2024,
author = {Fougeray, Ronan and Vidot, Loïck and Ratta, Marco and Teng, Zhaoyang and Skanji, Donia and Saint-Hilary, Gaëlle},
title = {Futility Interim Analysis Based on Probability of Success Using a Surrogate Endpoint},
journal = {Pharmaceutical Statistics},
year = {2024},
doi = {10.1002/pst.2410}
}
EUVIMED